Sato Tadashi, Liang Kaihui, Vaziri Nosratola D
Department of Pediatrics, Saga Medical School, Saga-City, Japan.
Kidney Int. 2003 Nov;64(5):1780-6. doi: 10.1046/j.1523-1755.2003.00281.x.
Imai rats exhibit spontaneous focal glomerulosclerosis (FGS) with progressive proteinuria and hyperlipidemia leading to renal insufficiency by age 34 weeks. Recently, we reported marked down-regulations of skeletal muscle and adipose tissue lipoprotein lipase (LPL) and very low-density lipoprotein (VLDL) receptor in male Imai rats at 32 weeks of age. Dietary protein restriction and oral adsorbent AST-120 (AST) have been shown to slow progression of renal disease and attenuate hyperlipidemia in the Imai rats. This study tested the hypothesis that amelioration of proteinuria by protein restriction or use of oral adsorbent AST-120 beginning at 10 weeks of age may improve renal disease and LPL and VLDL receptor deficiencies in Imai rats.
Ten-week-old male Imai rats were randomly assigned to those fed either a regular diet, low protein diet (LPD), or regular diet containing the adsorbent preparation, AST-120. Ten-week-old male Sprague-Dawley rats served as controls. The animals were observed for 24 weeks. Six rats were included in each group. All diets were prepared in powder form.
The untreated 34-week-old Imai rats showed severe proteinuria, hypoalbuminemia, 50% reduction in creatinine clearance, hypercholesterolemia, hypertriglyceridemia, and elevated plasma VLDL concentration. This was associated with significant reductions in plasma post-heparin LPL activity, hepatic lipase activity, as well as adipose tissue and skeletal muscle immunodetectable LPL and VLDL receptor proteins. Protein restriction mitigated the decline in creatinine clearance, ameliorated proteinuria, hypoalbuminemia, hypertension, and hypercholesterolemia, lowered plasma VLDL, and improved plasma postheparin LPL activity, hepatic lipase activity, LPL, and VLDL receptor proteins in skeletal muscle and adipose tissue. Similar improvements were observed in all parameters with AST administration.
Moderate protein restriction and use of oral adsorbent can slow progression of renal disease and, thereby, ameliorate LPL, hepatic lipase, and VLDL receptor deficiencies and the associated hyperlipidemia in rats with spontaneous FGS.
今井大鼠表现出自发性局灶性肾小球硬化(FGS),伴有进行性蛋白尿和高脂血症,到34周龄时会导致肾功能不全。最近,我们报道了32周龄雄性今井大鼠骨骼肌和脂肪组织脂蛋白脂肪酶(LPL)以及极低密度脂蛋白(VLDL)受体的显著下调。饮食蛋白限制和口服吸附剂AST - 120(AST)已被证明可减缓今井大鼠肾脏疾病的进展并减轻高脂血症。本研究检验了以下假设:从10周龄开始进行蛋白限制或使用口服吸附剂AST - 120改善蛋白尿,可能会改善今井大鼠的肾脏疾病以及LPL和VLDL受体缺陷。
将10周龄雄性今井大鼠随机分为三组,分别给予常规饮食、低蛋白饮食(LPD)或含吸附剂制剂AST - 120的常规饮食。10周龄雄性斯普拉格 - 道利大鼠作为对照。对动物进行24周的观察。每组包括6只大鼠。所有饮食均制成粉末状。
未经治疗的34周龄今井大鼠表现出严重蛋白尿、低白蛋白血症、肌酐清除率降低50%、高胆固醇血症、高甘油三酯血症以及血浆VLDL浓度升高。这与血浆肝素后LPL活性、肝脂酶活性以及脂肪组织和骨骼肌中可免疫检测到的LPL和VLDL受体蛋白的显著降低有关。蛋白限制减轻了肌酐清除率的下降,改善了蛋白尿、低白蛋白血症、高血压和高胆固醇血症,降低了血浆VLDL,并改善了血浆肝素后LPL活性、肝脂酶活性、骨骼肌和脂肪组织中的LPL以及VLDL受体蛋白。给予AST后,所有参数均有类似改善。
适度的蛋白限制和口服吸附剂的使用可以减缓肾脏疾病的进展,从而改善自发性FGS大鼠的LPL、肝脂酶和VLDL受体缺陷以及相关的高脂血症。